Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
CELC Transcript
Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call highlights strong potential for gedatolisib with a $5 billion market opportunity and extended patent exclusivity. Despite increased losses due to higher R&D and operational costs, the company has a solid cash position to support future growth. The Q&A section indicates positive analyst sentiment and excitement around clinical trial progress and market strategy. While some details remain unclear, the overall outlook is promising, suggesting a positive stock price movement.
Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript
Unknown8-15
The earnings call presents mixed signals: collaboration with renowned institutions and a solid cash position are positives, but increased losses and R&D expenses raise concerns. The Q&A revealed management's evasiveness on critical safety and competitive landscape details, which may dampen investor confidence. Despite potential in new drug trials, the lack of clear guidance and increased expenses suggest a neutral sentiment. Without market cap data, we assume a moderate reaction.
Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call reveals significant financial challenges, including increased net loss and operational expenses, without any share repurchase program to boost shareholder confidence. Despite optimistic market potential, regulatory and market adoption risks remain high. The Q&A section highlights management's reluctance to provide specific projections, which can increase investor uncertainty. No new partnerships or positive catalysts were announced. Overall, the financial outlook and management's evasive responses contribute to a negative sentiment, likely leading to a stock price decline in the range of -2% to -8%.
Celcuity at Needham Conference: New Frontiers in Cancer Treatment
Neutral4-10
CELC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
